Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Niche medicines make up over half of global research pipeline, reveals APBI

Over half of all medicines in the global research pipeline are specialty medicines — a paper from the Association of the British Pharmaceutical Industry has revealed — but it warns that there needs to be a “fundamental” change in health technology assessments (HTAs) if the UK is to adapt to the change.  

Stephen Whitehead

Stephen Whitehead, chief executive of the ABPI, wants to see the NHS work with industry to recruit patients for clinical trials

Specialty medicines are generally purchased through secondary care and are for smaller more niche disease areas — often orphan diseases, explained Stephen Whitehead, chief executive of the ABPI. Many personalised medicines fall under this category, he added. The ABPI’s discussion paper called “Securing a future for innovative medicines”, published to coincide with its annual conference last week (10 April 2014), says that the current HTA system means many oncology drugs are not being recommended by the National Institute for Health and Care Excellence. It suggests that the HTA system should treat oncology and non-oncology drugs differently. However, the paper praises NICE’s highly specialised technology programme, which only considers drugs for very rare diseases.

But it is not just medicines assessments that the ABPI would like to change. Mr Whitehead told PJ Online that there has to be a stronger research partnership between the NHS and industry because there is no longer a separation between the research and development phase and the commercial phase of a medicine. “Given the nature of the development of specialty medicines there has to be collaboration between the industry and the health system. This means working together to recruit patients for clinical trials and to collect real-world data,” he said. The ABPI says that 80 per cent of clinical trials do not meet their patient recruitment timelines, which is one reason for the rising cost of drug development.

Implementation of an electronic patient record would enable prospective observational studies and clinical trials to be conducted in the UK, the ABPI suggests. The report, which was produced in partnership with the Office for Health Economics, urges the UK to invest in e-health, saying that other countries have more comprehensive and complete anonymised medical data that can be used for healthcare research.

The ABPI welcomed news announced at the conference by Lord Howe, Parliamentary Under Secretary for Quality, that the Department of Health has created a senior post for a director general of innovation, growth and technology, a role that will oversee the medicine, pharmacy and industry division.

Citation: The Pharmaceutical JournalURI: 11137448

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • International Research in Healthcare

    International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.

    £34.99Buy now
  • Making Medicines

    Making Medicines

    An illustrated history of therapeutics and pharmacy, from the Egyptians through to the present day.

    £24.99Buy now
  • Non-prescription Medicines

    Non-prescription Medicines

    Reviews over-the-counter medicines, arranged by the conditions they are licensed to treat. Includes product recommendations.

    £34.99Buy now
  • Herbal Medicines

    Herbal Medicines

    Herbal Medicines provides a comprehensive single source of scientifically rigorous, impartial information on 180 of the most commonly used herbal medicinal products.

    £99.00Buy now
  • Stockley's Herbal Medicines Interactions

    Stockley's Herbal Medicines Interactions

    An invaluable reference for interactions of conventional medicines with herbal medicines, dietary supplements and nutraceuticals.

    £65.00Buy now
  • Popular Medicines

    Popular Medicines

    An illustrated history of some of the most popular branded medicines. Includes colourful historical adverts and details of the medicine's formula and intended purpose.

    £19.99Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Jobs you might like

Newsletter Sign-up

Get the latest emails sent to your inbox.